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j ourna l homepage: www.e lsev ie r .com/ locate /gynorCorrespondenceResponse to comment from Brasky et al.We thank Brasky et al. for their review (Brasky et al., 2016) of our
meta-analysis on the association between NSAID use and risk of endo-
metrial cancer (Verdoodt et al., 2016). We welcome the additional in-
formation on two of their studies, and the discussion points they have
raised, which are valuable contributions to the topics discussed in our
meta-analysis. Below we respond to the issues raised by Brasky et al.
Regarding the choice of point estimate for the VITAL cohort study
(Brasky et al., 2013), we have included a conservative estimate in our
analysis of regular aspirin use, leading to a pooled relative risk of 0.92
(95% CI = 0.84–1.00) for all cohort studies combined. Brasky et al. sug-
gest using a different estimate, which would yield a pooled relative risk
of 0.91 (95% CI = 0.83–0.99) (Brasky et al., 2016). Notwithstanding the
principal choice of estimate, we do not believe that the small difference
between the two pooled estimates for cohort studies justiﬁes changing
or adapting the conclusions in our meta-analysis, which were based on
risk estimates for both cohort and case-control studies, and on a number
of sensitivity and stratiﬁed analyses. Moreover, we do not support the
argument of Brasky et al. regarding the importance of statistical signiﬁ-
cance as this alone can not be used for proving a speciﬁc hypothesis or
measuring the importance of the result (Wasserstein and Lazar, 2016).
Decisions on the in- or exclusion of studies were based on pre-de-
ﬁned, objective criteria, as recommended by the Cochrane collaboration
for systematic reviews of interventions (Higgins and Green, 2011). We
avoided exclusion of studies based on subjective judgement of study
quality, but instead have provided a narrative discussion on the inﬂu-
ence of the heterogeneous character and potential biases of included
studies.
Finally, with regard to low-dose versus high-dose aspirin, we would
like to emphasise that the optimumdose and duration of aspirin use for
cancer prevention is still debated, and several studies have indicated
that low-dose aspirin (~75–150 mg) is as efﬁcient as higher-doseDOIs of original article: http://dx.doi.org/10.1016/j.ygyno.2015.12.009, http://
dx.doi.org/10.1016/j.gore.2016.04.007.
http://dx.doi.org/10.1016/j.gore.2016.10.007
2352-5789/© 2016 The Authors. Published by Elsevier Inc. This is an open access article underaspirin in preventing colorectal cancer (Cuzick et al., 2015). Naturally,
caution should be exercised in the interpretation of the results for
colorectal cancer in relation to other cancer sites, however, there is
increasing evidence that the underlying mechanisms for the anti-
neoplastic effects of aspirin are complex and not only related to cycloox-
ygenase inhibition and anti-inﬂammatory effects (Thun et al., 2012).
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